Venkata Viswanadh Edara

Medicine · Health Sciences

33h-index8.7kcitations60works7.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(50), COVID-19 Clinical Research Studies(31), Animal Virus Infections Studies(14), SARS-CoV-2 detection and testing(13), Immunotherapy and Immune Responses(9)

Publications60 total

5.1 – 00136 Plasma SIVmacM clonotypes in rebound viremia correspond to those induced by AZD5582 during ART
Journal of Virus Eradication·2024Open Access
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Science Translational Medicine·2024· 14 citedOpen Access
Author Correction: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
Nature·2023· 1 citedOpen Access
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
Structure·2023· 7 citedOpen Access
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
2022· 3 citedOpen Access
Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
Science Advances·2022· 44 citedOpen Access
Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine
Zenodo (CERN European Organization for Nuclear Research)·2022Open Access
Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine
Science Translational Medicine·2022· 58 citedOpen Access
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
Journal of Clinical Oncology·2022· 38 citedOpen Access
Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody
2022· 4 citedOpen Access
Defining the risk of SARS-CoV-2 variants on immune protection
Nature·2022· 178 citedOpen Access
Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine
2022· 5 citedOpen Access
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
Journal of Clinical Oncology·2022· 46 citedOpen Access
Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants
2022· 8 citedOpen Access
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Nature·2022· 686 citedOpen Access
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern
2022· 13 citedOpen Access
Molecular Basis of SARS-CoV-2 Omicron Variant Evasion from Shared Neutralizing Antibody Response
SSRN Electronic Journal·2022Open Access
The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters
2021· 87 citedOpen Access
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
2021· 40 citedOpen Access
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
2021· 129 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Mehul S. Suthar(47), Katharine Floyd(30), Lilin Lai(29), Jens Wrammert(16), Grace Mantus(15), Evan J. Anderson(14), Rafi Ahmed(13), Nadine Rouphael(12), Meredith E. Davis-Gardner(12), Susanne L. Linderman(11), Daniel C. Douek(10), Adrian B. McDermott(9), Nicole A. Doria‐Rose(9), Barney S. Graham(9), John R. Mascola(9), David C. Montefiori(9), Britta Flach(8), Matthew Gagné(8), Srilatha Edupuganti(8), Lindsay E. Nyhoff(8)